Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer.
Algorithms
Humans
Image Processing, Computer-Assisted
/ methods
Magnetic Resonance Imaging
/ methods
Organs at Risk
/ radiation effects
Pancreatic Neoplasms
/ radiotherapy
Particle Accelerators
/ instrumentation
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
/ methods
Radiotherapy, Image-Guided
/ methods
Radiotherapy, Intensity-Modulated
/ methods
IMRT
MR-guided Radiotherapy
online adaptive radiotherapy
pancreatic cancer
plan optimization
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
14
03
2019
revised:
19
07
2019
accepted:
22
07
2019
pubmed:
25
8
2019
medline:
27
2
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Magnetic resonance-guided adaptive radiotherapy (MRgART) is considered a promising resource for pancreatic cancer, as it allows to online modify the dose distribution according to daily anatomy. This study aims to compare the dosimetric performance of a simplified optimizer implemented on a MR-Linac treatment planning system (TPS) with those obtained using an advanced optimizer implemented on a conventional Linac. Twenty patients affected by locally advanced pancreatic cancer (LAPC) were considered. Gross tumor volume (GTV) and surrounding organ at risks (OARs) were contoured on the average 4DCT scan. Planning target volume was generated from GTV by adding an isotropic 3 mm margin and excluding overlap areas with OARs. Treatment plans were generated by using the simple optimizer for the MR-Linac in intensity-modulated radiation therapy (IMRT) and the advanced optimizer for conventional Linac in IMRT and volumetric modulated arc therapy (VMAT) technique. Prescription dose was 40 Gy in five fractions. The dosimetric comparison was performed on target coverage, dosimetric indicators, and low dose diffusion. The simplified optimizer of MR-Linac generated clinically acceptable plans in 80% and optimal plans in 55% of cases. The number of clinically acceptable plans obtained using the advanced optimizer of the conventional Linac with IMRT was the same of MR-Linac, but the percentage of optimal plans was higher (65%). Using the VMAT technique, it is possible to obtain clinically acceptable plan in 95% and optimal plans in 90% of cases. The advanced optimizer combined with VMAT technique ensures higher target dose homogeneity and minor diffusion of low doses, but its actual optimization time is not suitable for MRgART. Simplified optimization solutions implemented in the MR-Linac TPS allows to elaborate in most of cases treatment plans dosimetrically comparable with those obtained by using an advanced optimizer. A superior treatment plan quality is possible using the VMAT technique that could represent a breakthrough for the MRgART if the modern advancements will lead to shorter optimization times.
Identifiants
pubmed: 31444952
doi: 10.1002/acm2.12697
pmc: PMC6753732
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-30Informations de copyright
© 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Références
Radiother Oncol. 2017 Dec;125(3):470-477
pubmed: 28939180
Radiat Oncol. 2018 Mar 24;13(1):51
pubmed: 29573744
PLoS One. 2016 Dec 29;11(12):e0169202
pubmed: 28033342
Med Phys. 2015 Dec;42(12):7182-9
pubmed: 26632072
Ann Oncol. 2015 Apr;26(4):779-786
pubmed: 25623049
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71
pubmed: 22543215
Cancer J. 2011 May-Jun;17(3):182-9
pubmed: 21610472
Cureus. 2017 Aug 27;9(8):e1618
pubmed: 29104835
Med Phys. 2016 Jul;43(7):4040
pubmed: 27370123
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Phys Med Biol. 2009 Jun 21;54(12):N229-37
pubmed: 19451689
Semin Radiat Oncol. 2014 Jul;24(3):207-9
pubmed: 24931095
J Clin Oncol. 2013 Mar 1;31(7):886-94
pubmed: 23341531
J Neurosurg. 2006 Dec;105 Suppl:194-201
pubmed: 18503356
Pract Radiat Oncol. 2018 Sep - Oct;8(5):e312-e321
pubmed: 29703704
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Semin Radiat Oncol. 2014 Jul;24(3):196-9
pubmed: 24931092
Strahlenther Onkol. 2012 Jan;188(1):97-9
pubmed: 22234506
Radiother Oncol. 2017 Dec;125(3):439-444
pubmed: 28811038
Radiother Oncol. 2017 Nov;125(2):273-279
pubmed: 29079310
Phys Imaging Radiat Oncol. 2018 Jul 21;7:1-8
pubmed: 33458398